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Background 
Radioimmunotherapy (RIT) is an established treatment modality in Non-Hodgkin’s lymphoma (NHL).  The 
only two commercially available RITs - 
90
Y-ibritumomab tiuxetan (Zevalin®) is expensive and 
131
I-
tositumomab has been discontinued from commercial production.  In resource limited environment, 
90
Y-
ibritumomab tiuxetan and autologous haematopoietic stem cell transplantation (HSCT) might not be possible.  
Self-labelling 
131
I-rituximab might be the only viable practical option.  There is no randomized controlled trial 
comparing RIT versus autologous HSCT in NHL to examine the possibility of RIT substituting autologous 
HSCT. We reported our pioneer experience in Malaysia on self-labelling 
131
I-rituximab, substituting autologous 
HSCT and a patient, whom to our knowledge, is the first reported case received high dose 
131
I-rituximab (6000 
MBq or 163 mCi) combined with BEAM conditioning for autologous HSCT. 
Clinical Presentation 
Six patients (Diffuse Large B-cell Lymphoma (DLBCL) (n = 4), Follicular Lymphoma (FL) grade 2 (n = 2)), 
who were primary refractory/progressive except one and indicated but unable to receive autologous HSCT, and 
one primary refractory and progressive Primary Mediastinal (thymic) Large B-cell Lymphoma (PMBL), median 
age 60 (range 26-62), M:F = 6;1, received self-labelling 
131
I-rituximab from August to October 2014.  Six 
patients received the usual dosage and one patient with PMBL received high dose combined with BEAM 
conditioning autologous HSCT.  Median follow-up was 15.5 months (range 12.5-16.5).  They achieved 
complete response (CR) (except PMBL - partial response (PR)) as the best response.  At the latest follow-up, all 
the DLBCL remained in CR, one FL had slow progressive disease not symptomatic nor requiring intervention, 
one FL died after three months of 
131
I-rituximab due to rectal papillary mucinous adenocarcinoma which was 
symptomatic and diagnosed after 
131
I-rituximab, and the PMBL remained in PR.  In our very limited experience 
young patients age less than 60 tolerated the treatment well without grade 4 neutropaenia or thrombocytopaenia.  
Three out of four elderly patients age 60 or above developed grade 4 haematoloigcal toxicity, which might be 
related to undiagnosed bone marrow infiltration because two of them had FL.  Except for the patient who had 
developed rectal carcinoma and pre-existing myelodysplastic syndrome (MDS), none developed febrile 
neutropaenia or required antibiotics.  None developed hypothyroidism, myelodysplastic syndrome or acute 
myeloid leukaemia, albeit follow-up is still short. 
Intervention (& Technique) 
The usual dosage: 5 mCi on Day 0 (dosimetry dose) and total-body dose 0.75 Gy on Day 7 (therapeutic dose).   
High dose: 6000 MBq (163 mCi) on Day -18 combined with BEAM conditioning, started on Day -8, for 




I-rituximab may be a viable option to substitute autologous HSCT in refractory/relapse NHL, 
especially when autologous HSCT is not feasible.  It is is definitely cheaper and halves the cost of Zevalin®.  Its 
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